FDA's Patent-Based ANDA Exclusivity Policy Challenged By Apotex
This article was originally published in The Pink Sheet Daily
Executive Summary
Apotex files suit to force approval of its Prilosec ANDA, which is being held up by Andrx' exclusivity. Suit charges that FDA improperly granted Andrx additional period of exclusivity for omeprazole 40 mg based on a late-filed patent.
You may also be interested in...
FDA’s Patent-Based Approach Of Awarding Generic Exclusivity Upheld In Federal Court
Apotex is blocked from marketing a 40 mg generic of AstraZeneca’s Prilosec until April 2008.
FDA’s Patent-Based Approach Of Awarding Generic Exclusivity Upheld In Federal Court
Apotex is blocked from marketing a 40 mg generic of AstraZeneca’s Prilosec until April 2008.
Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma
The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.